Visão geral da empresa
A late-stage biotechnology firm, 4D Molecular Therapeutics, Inc. specializes in developing adeno-associated virus vectors derived from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution, which operates across the Netherlands and the United States. The company functions within the Healthcare sector, specifically the Biotechnology industry, a field characterized by high research intensity and significant capital requirements for product development. As of the latest reporting period, the organization employs 196 individuals and holds a market capitalization of $502.35M, generating annual revenue of $85.21M. These valuation and revenue figures position the company as a mid-cap entity within the biotech space, indicating a substantial asset base relative to many early-stage peers but reflecting the typical revenue challenges associated with pre-commercialization or late-stage drug development phases where costs often exceed immediate sales.
Saúde financeira
The company reported revenue of $85.21M over the trailing twelve months, accompanied by a net income of $-140,108,992 and an EBITDA of $-151,652,992. The substantial disparity between the positive revenue figure and the significant net loss highlights an aggressive cost structure typical of biotechnology firms, where expenses related to research, development, and vector engineering currently outweigh the revenue generated from current commercial activities. Free cash flow stands at $-54,154,876, indicating that the company is burning cash to fund its operations and pipeline advancement rather than generating surplus liquidity from its current business model. Despite the negative margins, the balance sheet shows a robust cash position of $402.66M against total debt of $21.41M, providing a significant cushion to cover obligations without immediate refinancing risks. The debt-to-equity ratio of 4.24 suggests a leveraged capital structure, yet the high current ratio of 9.39 indicates that the company holds ample current assets to cover its short-term liabilities, reflecting strong short-term liquidity. Return on Equity is recorded at -27.6% and Return on Assets at -17.3%, metrics that reveal that management is currently deploying equity and assets to generate losses rather than profits, a common scenario during the intensive development stages of biopharmaceutical companies.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -2.55, implying that the market prices the stock based on projected earnings that may eventually turn positive or relies on alternative valuation drivers common in biotech. The price-to-book ratio is 1.12, suggesting that the market values the company slightly above its net asset value, which can occur when investors assign a premium to the intellectual property and pipeline potential inherent in the biotechnology sector. Alternative valuation metrics such as the price-to-sales ratio of 5.90 and an EV/EBITDA of -0.80 provide further context, indicating that the stock price is heavily weighted against current sales rather than profitability, a standard practice for companies with limited commercial history but significant growth potential. Regarding price levels, the 52-week high is $12.34 and the low is $2.23, meaning the current trading price sits within a wide volatility range that reflects the speculative nature of the asset class. The beta value of 2.93 indicates that the stock is nearly three times as volatile as the broader market, meaning price swings will be significantly amplified by general market movements, which is characteristic of small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year is recorded at an extraordinary 8508900.0%, while earnings growth is N/A due to the company's current net loss status. The divergence between the astronomical revenue growth figure and the absence of earnings growth underscores that top-line expansion has not yet translated into profitability, implying that the company is still in a phase of scaling operations or recognizing revenue from specific milestones rather than commercial sales. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings, or rather the lack thereof, are not distributed to shareholders. Consequently, the company reinvests its resources into research and development activities to advance its pipeline rather than returning capital to investors. The overall growth and income profile presents a high-risk, high-potential scenario where shareholder returns are expected to materialize only after the company achieves commercial success with its lead product candidate and transitions from a cash-burning to a cash-generating entity.